Invirase
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Medicinal Chemistry is often referred to as a mature science. We believe that this is a misperception. What is probably more…
Saquinavir is a selective HIV protease inhibitor with limited systemic bioavailability (4% for the hard gelatin capsule (Invirase…
AIMS
Bioavailability of orally administered drugs depends on several factors including active excretion, e.g. by P-glycoprotein…
Two studies, concerning the synthesis of original nucleoside analogs regarded as an application of heterochemistry on…
AbstractBackground: PISCES (SV14604) was the largest study of antiretroviral therapy to assess clinical end-points. The study…
Cytochrome P450 3A4 (CYP3A4), the major phase I drug metabolizing enzyme in humans, and the MDR1 gene product P-glycoprotein (P…
The humoral immune response to HIV infection plays an important role in determining disease progression. Few and discordant…
In 1995 and 1996, the Food and Drug Administration (FDA) approved three products in the new protease inhibitor class of drugs…
Saquinavir, developed by Hoffmann-LaRoche under the trade name Invirase, is the first protease inhibitor to be approved by the…
: Saquinavir, developed by Hoffmann-LaRoche under the trade name Invirase, is the first protease inhibitor to be approved by the…